PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007
REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

GHENT, Belgium, Dec. 5, 2013 (GLOBE NEWSWIRE) -- REGULATED INFORMATION

Ablynx [Euronext Brussels: ABLX] today  announced, in accordance with  Article 
14 of  the Belgian  Law  of 2  May 2007  regarding  the publication  of  major 
shareholdings in  issuers  whose  securities  are admitted  to  trading  on  a 
regulated market (the "Transparency Law"), that it received a notification  of 
shareholdings from Perceptive Advisors LLC (US).

The above shareholder notified  that they have exceeded  the 3% threshold  and 
now hold  2,077,590 long-based  Ablynx shares,  which represent  4.24% of  the 
current 48,992,646 outstanding shares of Ablynx.

Full versions of all transparency  notifications are available on the  website 
of Ablynx, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on  single-domain 
antibody  fragments,  for  a  range  of  serious  human  diseases,   including 
inflammation, haematology, oncology and pulmonary disease. Today, the  Company 
has approximately  30  programmes in  the  pipeline and  seven  Nanobodies  at 
clinical development stage.  Ablynx has on-going  research collaborations  and 
significant partnerships with major pharmaceutical companies including AbbVie,
Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis.  The 
Company is headquartered in Ghent, Belgium.

More information can be found on www.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
 +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
e: ablynx@consilium-comms.com

pdf format of the press release http://hugin.info/137912/R/1748152/588740.pdf

HUG#1748152
 
Press spacebar to pause and continue. Press esc to stop.